Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: Results of a phase I study

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Dellas, Kathrin ^a,b   Reese, Thomas ^c   Richter, Michael ^d   Arnold, Dirk ^e   Dunst, Jürgen ^a,b  

^a North European Radiooncological Center Kiel (NRoCK)   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d Theoretical Surgery Unit   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Capecitabine; Chemoradiation; Oligometastatic colorectal cancer; Oxaliplatin; Phase I study

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DERMATITIS; DRUG EFFICACY; DYSPNEA; EPIGASTRIC DISCOMFORT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MALE; METASTASIS; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR GROWTH;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RADIOTHERAPY, CONFORMAL;

EID: 84861954158     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-83     Document Type: Article

References (19)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18(3):581-92.
2. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25(29):4575-80. 10.1200/JCO.2007.11.0833, 17925551.
3. Fokas E, Henzel M, Hamm K, Surber G, Kleinert G, Engenhart-Cabillic R. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol 2010, 186(4):210-7. 10.1007/s00066-010-2055-z, 20165820.
4. Freundt K, Meyners T, Bajrovic A, Basic H, Karstens JH, Adamietz IA, Rudat V, Schild SE, Dunst J, Rades D. Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. Strahlenther Onkol 2010, 186(4):218-23. 10.1007/s00066-010-2110-9, 20354660.
5. Heisterkamp C, Haatanen T, Schild SE, Rades D. Dose escalation in patients receiving whole-brain radiotherapy for brain metastases from colorectal cancer. Strahlenther Onkol 2010, 186(2):70-5. 10.1007/s00066-010-2067-8, 20127223.
6. Rades D, Kueter JD, Hornung D, Veninga T, Hanssens P, Schild SE, Dunst J. Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases. Strahlenther Onkol 2008, 184(12):655-62. 10.1007/s00066-008-1946-8, 19107346.
7. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27(10):1572-8. 10.1200/JCO.2008.19.6329, 19255321.
8. Rusthoven KE, Kavanagh BD, Burri SH, Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27(10):1579-84. 10.1200/JCO.2008.19.6386, 19255320.
9. Gerard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006, 24(28):4620-5. 10.1200/JCO.2006.06.7629, 17008704.
10. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009, 27(31):5124-30. 10.1200/JCO.2009.22.0467, 2773471, 19770376.
11. Hofheinz R, Wenz FK, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler MH, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Gencer D, Burkholder I, Hochhaus A. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. J Clin Oncol 2011, 29:3504.
12. Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010, 28(10):1638-44. 10.1200/JCO.2009.25.8376, 20194850.
13. Roedel C, Becker H, Fietkau R, Graeven U, Hohenberger W, Hothorn T, Lang-Welzenbach M, Liersch T, Staib L, Christiansen H, Wittekind C, Sauer R. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol 2011, 29:3505.
14. Roh MS, Yothers GA, O'Connell MJ, Beart RW, Pitot HC, Shields AF, Parda DS, Sharif S, Allegra CJ, Petrelli NJ, Landry JC, Ryan DP, Arora A, Evans TL, Soori GS, Chu L, Landes RV, Mohiuddin M, Lopa S, Wolmark N. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011, 29:3503. 10.1200/JCO.2011.35.7301, 21844503.
15. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial. J Clin Oncol 2011, 29(20):2773-80. 10.1200/JCO.2010.34.4911, 21606427.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-16. 10.1093/jnci/92.3.205, 10655437.
17. Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003, 21(16):3098-104. 10.1200/JCO.2003.02.505, 12915600.
18. Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Fürst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, Lordick F, Flentje M, Sülberg H, Hohenberger W, Sauer R. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007, 25(1):110-7.
19. Rödel C, Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 2007, 183(5):227-35. 10.1007/s00066-007-9000-9, 17497093.